Your browser doesn't support javascript.
loading
Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years.
Khor, Richard C; Bressel, Mathias; Tedesco, Jo; Tai, Keen Hun; Ball, David L; Duchesne, Gillian M; Farrugia, Helen; Yip, Wai Kuan; Foroudi, Farshad.
Afiliação
  • Khor RC; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. richard.khor@petermac.org.
  • Bressel M; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Tedesco J; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Tai KH; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Ball DL; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Duchesne GM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Farrugia H; Victorian Cancer Registry, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Yip WK; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Foroudi F; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Med J Aust ; 202(3): 153-5, 2015 Feb 16.
Article em En | MEDLINE | ID: mdl-25669479
ABSTRACT

OBJECTIVES:

To assess the tolerability and survival outcome of curative radiotherapy in patients over the age of 85 years. DESIGN, SETTING, AND

PARTICIPANTS:

Retrospective analysis of all patients aged over 85 years who received radiotherapy as part of curative treatment for any cancer (excluding insignificant skin cancers) at the Peter MacCallum Cancer Centre between 1 January 2000 and 1 January 2010. MAIN OUTCOME

MEASURES:

Poor treatment tolerability (defined as hospital admission during radiotherapy, treatment break, or early treatment cessation); predictors for poor treatment tolerability, overall survival and cancer-specific survival.

RESULTS:

327 treatment courses met eligibility criteria. The median age of patients was 87 years. The most common treatment sites were pelvis (30%), head and neck (25%), and breast (18%). The Eastern Cooperative Oncology Group performance status (ECOG PS) score was 0 or 1 for 70% of patients. Overall, 79% of patients completed the prescribed treatment without poor treatment tolerability, and 95% of patients completed all treatment. Only unfavourable ECOG PS score (odds ratio [OR], 1.80; P = 0.005) and increasing age (OR, 1.18; P = 0.018) predicted poor treatment tolerability. ECOG PS score predicted overall survival (hazard ratio, 1.53; P = 0.001).

CONCLUSION:

Age should not be the sole discriminator in decisions to prescribe aggressive loco-regional radiotherapy. ECOG PS score predicts for treatment tolerability, and also overall survival. The risk of cancer death was higher than non-cancer death for more than 5 years after treatment.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tolerância a Radiação / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tolerância a Radiação / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article